Compared with other H2 receptor antagonists, the Roxatidine contains higher selectivity for H2 receptors and features a stronger effect on acid suppression.
The combined market for H2 receptor antagonists and proton pump inhibitors, the two major GORD therapies currently in the marketplace, is estimated to be worth around US$25 billion.
on medications such as H2 receptor antagonists and proton pump inhibitors, a significant number of patients seek a permanent solution, as they are either unwilling to take chronic lifelong medications, or they are becoming increasingly unresponsive to high dose medications.